HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter...
Hence then, the article about akeso presents updated data on cadonilimab combination therapy in pd l 1 inhibitor resistant advanced nsclc at elcc 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026 )
Also on site :
- Trump endorses Steven Hilton in California governor's race
- 10 Years Ago Today, Country Music Legend Died on His 79th Birthday After Eerily Predicting He Would
- This 1954 Film Ranked as Alfred Hitchcock's No. 1 'Masterpiece'